Abstract:Interleukin (IL)-15 is a promising immunotherapeutic cytokine for cancer treatment because it can stimulate the proliferation and cytotoxicity of CD8+ T lymphocytes and nature killer (NK) cells, similar to the action of IL-2, which has been used to treat metastatic melanoma and renal cancer. IL-15 may have improved pharmacologic properties over IL-2 because it doesn't cause vascular leak syndrome or stimulate regulatory T cells. However, IL-15 is difficult to express as a stable soluble protein and has a short half-life in vitro and in vivo. To solve the problem, we designed an IL-15 ultralong CDR3 humanized bovine antibody fusion. Bovine ultralong CDR3 antibodies have a unique "stalk and knob" structure in which two antiparallel β-strands support a disulfide bonded knob protruding out of the antibody surface and forms a mini antigen binding domain. By replacing the knob domain with IL-15, we have created a chimeric CDR3-IL-15 IgG which functions as IL-15 in vitro and in vivo but can be easily produced in mammalian cells with increased stability. Thus, the CDR3 can stabilize IL-15 in the absence of its high affinity receptor α (Rα) chain. Furthermore, as IL-15 utilizes Rα for increased trans signaling to the receptor β and γ subunits, one variant candidate (CDR3-IL-15_Rα) was produced by co-expressing Rα sushi domain with the chimeric IgG. Both constructs have been demonstrated to be highly active in stimulating proliferation of NK cells and CD8+ T cells in vitro as well as in stimulating proliferation of NK cells and CD8+ T cells in rats and non-human primates (NHP). Although the CDR3-IL-15_Rα exhibited higher in vitro signaling activity than CDR3-IL-15, both were equally potent in stimulating the proliferation of NK cells and CD4+ and CD8+ T cells in NHP without any immunogenicity detected. Moreover, in vivo studies in NHP indicated that CDR3-IL-15 acted faster than CDR3-IL-15_Rα in stimulating the proliferation of these lymphocytes. CDR3-IL-15 is the first thermodynamically stabilized variant of IL-15 produced in the absence of its Rα chain, is highly active in vivo, and has multiple potential cancer applications as an T and NK cell stimulating agent. Citation Format: Ruiqi Huang, Duncan McGregor, Vaughn Smider. Ultralong CDR3 engineered interleukin-15 antibody fusion for T and NK cell expansion [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5811.

Recombinant human interleukin 15 long peptide fragment and production method thereof

Gene Cloning and Construction of Prokaryotic and Plant Expression Vectors of I?L15/PAP Fusion Protein

Activity of Recombinant Human Interleukin-15 Against Tumor Recurrence and Metastasis in Mice

ANTITUMOR EFFECTS OF HUMAN IL-15 GENE MODIFIED LUNG CANCER CELL LINE

Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives

Codon Optimization, Expression, Purification, and Functional Characterization of Recombinant Human IL-25 in Pichia Pastoris

Identification and Purification of Recombinant Human Interleukin-12

Expression and Purification of Recombinant Human Interleukin-11 in Pichia Pastoris

Preliminary Studies on High Cell Density Fermentation of the Recombinant Human Interluekin-15 in E.coli

Oxidation and reduction analysis of therapeutic recombinant human interleukin-15 by HPLC and LC-MS

The High-Concentration Refolding, Purification and Bioactivity Assay of Recombinant Human Interleukin-18

Expression, purification, and biological characterization of recombinant human interleukin-31 protein

Expression, Purification, and Polyethylene Glycol Site-Specific Modification of Recombinant Human Interleukin 24 in Escherichia coli

Functional Characterization Of Interleukin-15 Gene Transduction Into The Human Natural Killer Cell Line Nkl

[Prokaryotic expression, purification, refolding and biological assays of recombinant human interleukin 4 inclusion body]

Expression of Recombinant Human Interleukin-13 in Pichia Pastoris and Its Bioactivity in Vitro

High-level Soluble Expression, Purification, and Functional Characterization of the Recombinant Human Leukemia Inhibitory Factor: a Potential General Strategy for the Recombinant Expression of Cytokines Consisting of Four Α-Helices in a Bundle.

Purification and Characterization of Non-Fusion Recombinant Human Interleukin-18 Expressed in E. Coli

Abstract 5811: Ultralong CDR3 engineered interleukin-15 antibody fusion for T and NK cell expansion

A Novel Method for Biological Activity Determination of Recombinant Human Interluekin-8

A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities